PATIENT AND PUBLIC INVOLVEMENT (PPI) PROJECT MANAGER
Tamara Kohler
+41 31 307 10 46
Tamara Kohler
+41 31 307 10 46
A partnership based on both mutual trust and transparent communication is what forms the foundation of a dialogue between researchers and those affected by research. The SCTO promotes this dialogue and advocates for the support and implementation of patient and public involvement (PPI) in academic clinical research.
Patient and public involvement (PPI) in clinical research can be defined as research that is carried out with or by patients or members of the public instead of to, about, or for them. It means they are involved in a research project or initiative as equal partners, for example by:
Our PPI Fact Sheet explains where and when PPI is possible and who should be involved. We prepared this fact sheet in close collaboration with the Swiss National Science Foundation (SNSF).
One of our most important strategic objectives for the 2021–2024 funding period is to promote PPI in academic clinical research and implement it in a sustainable manner. We view compensation as one aspect of sustainability in this context, which is why we advocate for financial compensation that is based on the principles of fairness. This demonstrates that the contributions patients and the public make are valuable and appreciated.
To facilitate the compensation of patients and representatives of the public for their research contributions, we have developed a PPI remuneration policy that can be used by clinical research projects in our network. Our SCTO Remuneration Policy for Patient and Public Involvement (PPI) Activities also provides guidelines for reimbursing travel and accommodation expenditures.
As a first step toward answering this question, we worked together with our partner organisations.* Using an online survey, a multistakeholder working group identified and characterised a wide variety of PPI initiatives and projects. The results of this survey as well as information about other PPI initiatives and projects (as of October 2022) are available on our PPI mapping page.
*Swiss Academy of Medical Sciences (SAMS), Swiss Personalized Health Network (SPHN), Swiss Group for Clinical Cancer Research (SAKK)
PPI is also an important topic for institutions that fund clinical research projects, for example the Swiss National Science Foundation (SNSF). The SNSF includes PPI representatives in the international evaluation panel for its Investigator Initiated Clinical Trials (IICT) programme; these representatives evaluate the PPI aspects of proposed clinical trials.
Our PPI Guide for Researchers helps researchers identify opportunities to include effective and meaningful PPI in their clinical trials. We prepared this fact sheet in close collaboration with the SNSF.